Literature DB >> 23545048

How can we trick the immune system into overcoming the detrimental effects of oncolytic viral therapy to treat glioblastoma?

Walter H Meisen, Balveen Kaur.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 23545048      PMCID： PMC5298807          DOI： 10.1586/ern.13.25

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN： 1473-7175            Impact factor:   4.618


× No keyword cloud information.
  19 in total

1.  China approves world's first oncolytic virus therapy for cancer treatment.

Authors:  Ken Garber
Journal:  J Natl Cancer Inst       Date:  2006-03-01       Impact factor: 13.506

2.  Using clinically approved cyclophosphamide regimens to control the humoral immune response to oncolytic viruses.

Authors:  K-W Peng; R Myers; A Greenslade; E Mader; S Greiner; M J Federspiel; A Dispenzieri; S J Russell
Journal:  Gene Ther       Date:  2012-04-05       Impact factor: 5.250

3.  Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors.

Authors:  J N Parker; G Y Gillespie; C E Love; S Randall; R J Whitley; J M Markert
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-29       Impact factor: 11.205

Review 4.  Impact of tumor microenvironment on oncolytic viral therapy.

Authors:  Jeffrey Wojton; Balveen Kaur
Journal:  Cytokine Growth Factor Rev       Date:  2010 Apr-Jun       Impact factor: 7.638

5.  Bevacizumab with angiostatin-armed oHSV increases antiangiogenesis and decreases bevacizumab-induced invasion in U87 glioma.

Authors:  Wei Zhang; Giulia Fulci; Jason S Buhrman; Anat O Stemmer-Rachamimov; John W Chen; Gregory R Wojtkiewicz; Ralph Weissleder; Samuel D Rabkin; Robert L Martuza
Journal:  Mol Ther       Date:  2011-09-13       Impact factor: 11.454

6.  Copper chelation enhances antitumor efficacy and systemic delivery of oncolytic HSV.

Authors:  Ji Young Yoo; Jason Pradarelli; Amy Haseley; Jeffrey Wojton; Azeem Kaka; Anna Bratasz; Christopher A Alvarez-Breckenridge; Jun-Ge Yu; Kimerly Powell; Andrew P Mazar; Theodoros N Teknos; E Antonio Chiocca; Joseph C Glorioso; Matthew Old; Balveen Kaur
Journal:  Clin Cancer Res       Date:  2012-07-02       Impact factor: 12.531

7.  Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated Treg modulation and interleukin-2.

Authors:  Timothy Kottke; Jill Thompson; Rosa Maria Diaz; Jose Pulido; Candice Willmon; Matt Coffey; Peter Selby; Alan Melcher; Kevin Harrington; Richard G Vile
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

8.  Trichostatin A and oncolytic HSV combination therapy shows enhanced antitumoral and antiangiogenic effects.

Authors:  Ta-Chiang Liu; Pedro Castelo-Branco; Samuel D Rabkin; Robert L Martuza
Journal:  Mol Ther       Date:  2008-04-01       Impact factor: 11.454

9.  Oncolytic HSV-1 infection of tumors induces angiogenesis and upregulates CYR61.

Authors:  Kazuhiko Kurozumi; Jayson Hardcastle; Roopa Thakur; Joshua Shroll; Michal Nowicki; Akihiro Otsuki; E Antonio Chiocca; Balveen Kaur
Journal:  Mol Ther       Date:  2008-06-10       Impact factor: 11.454

10.  Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy.

Authors:  Kazuhiko Kurozumi; Jayson Hardcastle; Roopa Thakur; Ming Yang; Gregory Christoforidis; Giulia Fulci; Fred H Hochberg; Ralph Weissleder; William Carson; E Antonio Chiocca; Balveen Kaur
Journal:  J Natl Cancer Inst       Date:  2007-11-27       Impact factor: 13.506
View more
  7 in total

1.  Bortezomib Treatment Sensitizes Oncolytic HSV-1-Treated Tumors to NK Cell Immunotherapy.

Authors:  Ji Young Yoo; Alena Cristina Jaime-Ramirez; Chelsea Bolyard; Hongsheng Dai; Tejaswini Nallanagulagari; Jeffrey Wojton; Brian S Hurwitz; Theresa Relation; Tae Jin Lee; Michael T Lotze; Jun-Ge Yu; Jianying Zhang; Carlo M Croce; Jianhua Yu; Michael A Caligiuri; Matthew Old; Balveen Kaur
Journal:  Clin Cancer Res       Date:  2016-07-07       Impact factor: 12.531

2.  The oncolytic efficacy and safety of avian reovirus and its dynamic distribution in infected mice.

Authors:  Ruimin Cai; Guangyuan Meng; Yi Li; Wenyang Wang; Youxiang Diao; Shuping Zhao; Qiang Feng; Yi Tang
Journal:  Exp Biol Med (Maywood)       Date:  2019-07-12

Review 3.  To Infection and Beyond: The Multi-Pronged Anti-Cancer Mechanisms of Oncolytic Viruses.

Authors:  Kevin A Cassady; Kellie B Haworth; Josh Jackson; James M Markert; Timothy P Cripe
Journal:  Viruses       Date:  2016-02-04       Impact factor: 5.048

4.  Reolysin and Histone Deacetylase Inhibition in the Treatment of Head and Neck Squamous Cell Carcinoma.

Authors:  Alena C Jaime-Ramirez; Jun-Ge Yu; Enrico Caserta; Ji Young Yoo; Jianying Zhang; Tae Jin Lee; Craig Hofmeister; John H Lee; Bhavna Kumar; Quintin Pan; Pawan Kumar; Robert Baiocchi; Theodoros Teknos; Flavia Pichiorri; Balveen Kaur; Matthew Old
Journal:  Mol Ther Oncolytics       Date:  2017-05-10       Impact factor: 7.200

Review 5.  The Role of NK Cells and Innate Lymphoid Cells in Brain Cancer.

Authors:  Alexander James Sedgwick; Nazanin Ghazanfari; Patrick Constantinescu; Theo Mantamadiotis; Alexander David Barrow
Journal:  Front Immunol       Date:  2020-07-31       Impact factor: 7.561

Review 6.  Combination therapy with CAR T cells and oncolytic viruses: a new era in cancer immunotherapy.

Authors:  Ramazan Rezaei; Hadi Esmaeili Gouvarchin Ghaleh; Mahdieh Farzanehpour; Ruhollah Dorostkar; Reza Ranjbar; Masoumeh Bolandian; Majid Mirzaei Nodooshan; Akbar Ghorbani Alvanegh
Journal:  Cancer Gene Ther       Date:  2021-06-22       Impact factor: 5.854

Review 7.  Prospects for combined use of oncolytic viruses and CAR T-cells.

Authors:  Adam Ajina; John Maher
Journal:  J Immunother Cancer       Date:  2017-11-21       Impact factor: 13.751
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.